Patents by Inventor Kathryn Emma Matthews

Kathryn Emma Matthews has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7524500
    Abstract: Methods and compositions for stimulating the growth, proliferation, differentiation and/or mobilization of stem and/or progenitor cells are described. The method involves administering an effective amount of a substance which can activate the CD163 hemoglobin scavenger receptor signal transduction pathway. The methods and compositions are useful in stimulating hematopoiesis and in treating a wide range of conditions including cytopenias, anemias and for use in preparing cells for transplantation.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: April 28, 2009
    Assignee: Therapure Biopharma Inc.
    Inventors: Susan Mueller, David Bell, Kathryn Emma Matthews
  • Publication number: 20040151692
    Abstract: Methods and compositions for stimulating the growth, proliferation, differentiation and/or mobilization of stem and/or progenitor cells are described. The method involves administering an effective amount of a substance which can activate the CD163 hemoglobin scavenger receptor signal transduction pathway. The methods and compositions are useful in stimulating hematopoiesis and in treating a wide range of conditions including cytopenias, anemias and for use in preparing cells for transplantation.
    Type: Application
    Filed: March 26, 2004
    Publication date: August 5, 2004
    Inventors: Susan Mueller, David Bell, Kathryn Emma Matthews
  • Patent number: 6361998
    Abstract: The present invention describes a serum-free medium that promotes the growth and differentiation of erythroid cells, cells that are highly transducible by a non-viral method and genes which increase the growth of erythroid cells and decrease their dependency on Epo. This invention can be used in the expansion of hematopoietic stem cells to produce cultures of erythroid cells as a source of erythroid-specific proteins such as hemoglobin. Hematopoietic stem cells are cultured ex vivo in a serum-free culture medium with the addition of IL-3, SCF and EPO. Cells transfected with the gene described in the present invention can be cultured in the serum-free culture medium with decreased dependency on Epo and other cytokines, thereby reducing the cost of the production of hemoglobin.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: March 26, 2002
    Assignee: Hemosol Inc.
    Inventors: David N. Bell, Kathryn Emma Matthews, Susan G. Mueller